Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04577755 · ClinicalTrials.gov registry record · Phase 2
Pomalidomide Treatment in Patients With Kaposi Sarcoma
A Phase 2 study of Skin Kaposi Sarcoma, sponsored by National Cancer Institute (NCI).
- Active
- Registry status
- Phase 2
- Development phase
- 45
- Enrollment target
- 15
- Study locations
NCT04577755: Active Phase 2 study of Skin Kaposi Sarcoma, sponsored by National Cancer Institute (NCI).
NCT04577755 is a Phase 2 study of Skin Kaposi Sarcoma that is active but no longer recruiting, run by National Cancer Institute (NCI). The registered enrollment target is 45 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (66% lower). The trial reports 15 study locations across 11 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04577755, a Phase 2 study of Skin Kaposi Sarcoma, is active but no longer recruiting, sponsored by National Cancer Institute (NCI).
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 45 participants
- Enrollment target
- 15
- Study locations
Study Summary
This phase II trial studies the effect of pomalidomide in treating patients with Kaposi sarcoma. Pomalidomide is a cancer fighting drug that stops the growth of blood vessels, stimulates the immune system, and may kill cancer cells.
Primary Outcome
The Kaplan-Meier (K-M) method will be used to describe duration of response for all treated participants. The cumulative proportion of study participants still in response at one year will be estimated using the point estimate and the 95% confidence interval using Greenwood's formula for the standard error of the K-M estimate. The proportional hazards model will be used to evaluate the association of human immunodeficiency virus (HIV) status and pretreatment status on duration of response.
Conditions Studied
Interventions
- PROCEDURE Biospecimen Collection
- PROCEDURE Computed Tomography
- PROCEDURE Biopsy Procedure
- PROCEDURE X-Ray Imaging
- DRUG Pomalidomide
Study Locations (15)
New York
- Mount Sinai Hospital - New York
- NYP/Weill Cornell Medical Center - New York
- Montefiore Medical Center-Einstein Campus - The Bronx
Pennsylvania
- University of Pennsylvania/Abramson Cancer Center - Philadelphia
- Pennsylvania Hospital - Philadelphia
Texas
- Thomas Street at Quentin Mease Health Center - Houston
- M D Anderson Cancer Center - Houston
California
- UC San Diego Moores Cancer Center - La Jolla
Florida
- Miami Cancer Institute - Miami
Illinois
- University of Illinois - Chicago
Maryland
- Johns Hopkins University/Sidney Kimmel Cancer Center - Baltimore
Massachusetts
- Boston Medical Center - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 45 participants |
| Start Date | 2022-03-18 |
| Est. Completion | 2026-10-01 |
| Phase | Phase 2 |
What the registry record for NCT04577755 still lists
NCT04577755 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 45 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (66% lower).
The record links to 1 condition, with Skin Kaposi Sarcoma appearing as the primary indexed condition, and to 5 interventions - of which Biospecimen Collection is the first listed.
NCT04577755 lists 15 locations in 11 states (New York, Pennsylvania, Texas).
Frequently Asked Questions
What is clinical trial NCT04577755 about?
NCT04577755 is a clinical study titled "Pomalidomide Treatment in Patients With Kaposi Sarcoma". This phase II trial studies the effect of pomalidomide in treating patients with Kaposi sarcoma. Pomalidomide is a cancer fighting drug that stops the growth of blood vessels, stimulates the immune system, and may kill cancer cells.
What is the current status of trial NCT04577755?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 45 participants. The study started on 2022-03-18. Estimated completion is 2026-10-01.
What conditions does trial NCT04577755 study?
This clinical trial studies the following conditions: Skin Kaposi Sarcoma.
What interventions are being tested in trial NCT04577755?
The interventions under investigation include: Biospecimen Collection (PROCEDURE), Computed Tomography (PROCEDURE), Biopsy Procedure (PROCEDURE), X-Ray Imaging (PROCEDURE), Pomalidomide (DRUG).
Who is sponsoring clinical trial NCT04577755?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04577755 being conducted?
This trial has 15 study locations across California, Florida, Illinois, Maryland, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04577755's enrollment target sits among peer trials
45 1296th of 2000 higher than 679 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00804154 · 45 participants · Phase 1
Resiniferatoxin to Treat Severe Pain Associated With Advanced Cancer
- NCT01851694 · 45 participants · NA
Beta-cell Response to Incretin Hormones in Cystic Fibrosis
- NCT02896335 · 45 participants · Phase 2
Palbociclib and Pembrolizumab In Central Nervous System Metastases
- NCT03454035 · 45 participants · Phase 1
Ulixertinib/Palbociclib in Patients With Advanced Pancreatic and Other Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI